共 116 条
[1]
Kamm CP(2014)Multiple sclerosis: current knowledge and future outlook Eur Neurol 72 132-41
[2]
Uitdehaag BM(2014)Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis Mult Scler Relat Disord 3 294-302
[3]
Polman CH(2014)Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies Mayo Clin Proc 89 225-40
[4]
Reder AT(2008)Tolerability, adherence, and patient outcomes Neurology 71 S21-3
[5]
Oger JF(2011)Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis Eur J Neurol 18 1343-9
[6]
Kappos L(2015)Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program BMC Neurol 15 170-83
[7]
O'Connor P(2014)DAWN Japan group. Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study Curr Med Res Opin 30 177-80
[8]
Rametta M(2014)Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes BMC Neurol 14 49-47
[9]
Wingerchuk DM(2012)Patient preferences and healthcare outcomes: an ecological perspective Expert Rev Pharmacoecon Outcomes Res 12 167-42
[10]
Carter JL(2013)Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study BMC Neurol 13 117-76